loader2
Partner With Us NRI

Neuland Laboratories Ltd share Price Today

Company details

12,514.90
13,630.00
3,611.10
13,630.00
6M Return 100.33%
1Y Return 235.59%
Mkt Cap.(Cr) 16,410.21
Volume 1,13,591
Div Yield 0.11%
OI
-
OI Chg %
-
Volume 1,13,591

Invest in Market with Confidence: High performance strike rate of over 72%

Trade, sell, withdraw – all in minutes!
icon 27 Years

of legacy

icon 4.4 Star

App Rating

icon 1 Crore +

Customers

Open a Trading Account

Achieve your Investment goals today!

+91
Please enter valid Mobile Number

Pharmaceuticals company Neuland Laboratories announced Q1FY25 results:

  • Total Income: Rs 444.4 crore, reflecting a YoY growth of 21.7% compared to Q1FY24 (Rs 365.0 crore) and a QoQ growth of 13.8% from Q4FY24 (Rs 390.4 crore).
  • EBITDA: Rs 128.6 crore, representing a 29.5% increase from Q1FY24 (Rs 99.3 crore) and a 14.7% rise from Q4FY24 (Rs 112.2 crore).
  • EBITDA Margin: 28.9%, an increase of 174 basis points from Q1FY24 (27.2%) and a slight increase of 21 basis points from Q4FY24 (28.7%).
  • Exceptional Item: Rs 20.6 crore (noted for the quarter).
  • Profit After Tax (PAT): Rs 98.3 crore, up 58.0% from Q1FY24 (Rs 62.2 crore) and a 45.5% increase from Q4FY24 (Rs 67.6 crore).
  • PAT Margin: 22.1%, a growth of 510 basis points compared to Q1FY24 (17.0%) and up 480 basis points from Q4FY24 (17.3%).
  • Earnings Per Share (EPS): Rs 76.6, reflecting a 58.0% increase from Q1FY24 (Rs 48.5) and a 45.5% rise from Q4FY24 (Rs 52.7).

Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We recorded our highest ever quarterly revenues in Q1FY25 led by growth in the CMS business even as we recorded healthy EBITDA margins. We continue to maintain that FY25 will be a year of normalisation of revenue growth and subsequently margins as we continue to invest for growth. We expect our business to regain momentum from FY26 onwards basis our visibility from our portfolio of projects and products.”

In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “The CMS revenues were driven by commercial molecules in line with our expectations as we outline our strategy over the years. As we evaluate our pipeline of projects and the flow of new projects, we remain enthusiastic on the strong potential of the CMS business over the long term. The GDS business continues to build on the strong base we have with quality focussed customers, even as our R&D team is working on an exciting set of molecules to add to our portfolio.”

Result PDF

View Other Company Results

Neuland Laboratories Ltd shares SWOT Analysis

Strengths (18)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Company with high TTM EPS Growth
  • Strong Annual EPS Growth

Weakness (0)

Data not found

Opportunity (4)

  • Negative to Positive growth in Sales and Profit with Strong Price momentum
  • Highest Recovery from 52 Week Low
  • RSI indicating price strength

Threats (2)

  • Promoter decreasing their shareholding
  • High PE (PE > 40)

Resistance and support

R1 13,442.0
R2 14,093.6
R3 14,557.1
Pivot

12,978.47

S1 12,326.9
S2 11,863.4
S3 11,211.8
EMA SMA
12,496.6
11,433.8
9,954.9
8,209.7
12,670.7
11,442.8
9,158.3
7,728.0
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
SMALLCAP WORLD FUND INC Bulk Purchase 2024-06-26 7400 130000 BSE
MALABAR INDIA FUND LIMITED Bulk Sell 2024-06-26 7400 130000 BSE
SMALLCAP WORLD FUND INC Block Purchase 2024-06-26 7400 130000 BSE
Name Category Shares
RAMAMOHAN RAO DAVULURI PROMOTER 21.59%
DAVULURI VIJAYA RAO PROMOTER 4.78%
DAVULURI SUCHETH RAO PROMOTER 2.63%
DAVULURI SAHARSH RAO PROMOTER 2.24%
DAVULURI ROHINI NIVEDITHA RAO PROMOTER 0.67%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Neuland Laboratories Ltd Stocks COMPARISON

Financials( in Cr) Neuland Laboratories Ltd Sun Pharmaceuticals Industries Ltd Divis Laboratories Ltd Cipla Ltd Torrent Pharmaceuticals Ltd
Price 12,790.50 1,948.70 5,457.90 1,672.50 3,482.60
% Change -1.67 4.31 1.53 2.13 0.34
Mcap Cr 16,410.21 4,67,558.41 1,44,890.33 1,35,057.39 1,17,866.86
Revenue TTM Cr 1,558.58 48,496.85 7,845.00 25,774.09 10,727.84
Net Profit TTM Cr 300.08 9,648.44 1,600.00 4,155.31 1,656.38
PE TTM 50.65 44.34 86.44 30.37 70.40
1 Year Return 235.59 73.36 46.38 41.82 88.54
ROCE 33.01 17.20 16.41 22.27 23.21
ROE 26.38 16.13 12.15 16.58 25.38
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 1,282.70 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 17,492.71 71,886.12
LAST 3M 78,204.11 61,813.64
LAST 6M 1,87,352.46 86,996.15
LAST 12M 3,32,953.72 1,53,700.57

Neuland Laboratories Ltd Information

Stock PE (TTM)
50.65
Promoter Holding
32.74%
Book Value
999.0697
ROCE
33.01%
ROE
26.38%
Description
  • Set up in 1984 as a private limited company to manufacture bulk drugs, Neuland Laboratories (NLL) is promoted by D R Rao. Neuland Drugs & Pharmaceuticals Pvt Ltd, a company set up by the same promoters to manufacture bulk drugs was merged with NLL with effect from Apr.`92. NLL manufactures bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. It came out with its initial public offering in Apr.`94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.7 cr. NLL`s products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate. During the year 1999-2000, the company introduced Itraconazole, an anti-fungal drug and Ipratropium Bromide, an anti-asthmatic drug and the R & D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form. Mirtrazapine, an anti-depressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI. The Company commenced commercial production of Ramipril, a cardiovascular drug for export to certain markets in 2002. The Company commenced commercial production of Citalopram Hydrobromide, an anti depressant, Pirbuterol Acetate, a bronchodilator, Levofloxacin, an anti bacterial, Levetiracetam, an anti convulsant in 2003. A subsidiary company of Neuland Laboratories Ltd was incorporated on January 4, 2007 in the State of Delaware, USA with its principal office in Orange County, California. During the year 2008-2009, Neuland Laboratories K.K., Japan was incorporated as a subsidiary of Company.

No Data Found

AGM Date (Month) : Jul
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 524558
NSE Code : NEULANDLAB
Book Closure Date (Month) : Jul
BSE Group : A
ISIN : INE794A01010

FAQ’s on Neuland Laboratories Ltd Shares

You can buy Neuland Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Neuland Laboratories Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Sep 27, 2024 04:00 PM the closing price of Neuland Laboratories Ltd was Rs.12,790.50.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Sep 27, 2024 04:00 PM, the market cap of Neuland Laboratories Ltd stood at Rs. 16,410.21 Cr.

The latest PE ratio of Neuland Laboratories Ltd as of Sep 27, 2024 04:00 PM is 50.65

The latest PB ratio of Neuland Laboratories Ltd as of Sep 27, 2024 04:00 PM is 0.08

The 52-week high of Neuland Laboratories Ltd share price is Rs. 13,630.00 while the 52-week low is Rs. 3,611.10

According to analyst recommendations, Neuland Laboratories Ltd Share has a "" rating for the long term.

Download App

Download Our App

Play Store App Store
market app

Open a Trading Account

Achieve your Investment goals today!

+91
Please enter valid Mobile Number